BRIEF published on 06/10/2026 at 20:18, 4 months 28 days ago Poxel nomme Yves Decadt PDG pour faire progresser ses objectifs stratégiques Partenariats Stratégiques Biopharmaceutique Poxel Iméglimine Yves Decadt
BRIEF published on 06/10/2026 at 20:18, 4 months 28 days ago Poxel nomme Yves Decadt comme nouveau Directeur Général Partenariats Stratégiques Biopharmaceutique Plan De Continuation Poxel Yves Decadt
PRESS RELEASE published on 06/10/2026 at 20:13, 4 months 28 days ago Inside Information / Other news releases Poxel appoints Yves Decadt as Chief Executive Officer to accelerate portfolio development and strategic partnerships. Yves Decadt brings over 25 years of international pharmaceutical industry experience Strategic Partnerships Chief Executive Officer Portfolio Development Poxel Yves Decadt
PRESS RELEASE published on 06/10/2026 at 20:13, 4 months 28 days ago Informations privilégiées / Autres communiqués Poxel nomme Yves Decadt Directeur Général pour accélérer la valorisation du portefeuille et les partenariats stratégiques. Continuité et ambition commerciale confirmée Partenariats Poxel PXL065 Iméglimine Yves Decadt
BRIEF published on 03/31/2026 at 13:12, 7 months 8 days ago Poxel Sells PXL770 to Scynexis for Up to $196 Million Biopharmaceutical Poxel PXL770 SCYNEXIS ADPKD
BRIEF published on 03/31/2026 at 13:12, 7 months 8 days ago Poxel vend le PXL770 à Scynexis pour un montant pouvant atteindre 196 millions de dollars Biopharmaceutique Poxel PXL770 SCYNEXIS ADPKD
BRIEF published on 03/31/2026 at 13:12, 7 months 8 days ago Poxel cède le PXL770 à Scynexis pour une valeur potentielle de 196 millions de dollars Accord Financier Poxel PXL770 SCYNEXIS Polykystose Rénale
BRIEF published on 03/31/2026 at 13:12, 7 months 8 days ago Poxel sells the PXL770 to Scynexis for a potential value of $196 million Financial Agreement Poxel PXL770 SCYNEXIS Polycystic Kidney Disease
PRESS RELEASE published on 03/31/2026 at 13:07, 7 months 8 days ago Inside Information / Operations of the issuer (acquisitions, sales...) Poxel announces sale of PXL770 for up to $196 million to SCYNEXIS. PXL770 targets ADPKD. Agreement includes upfront payment, development and commercial milestones. Phase 2 study planned for Q4 2026 Milestones Poxel PXL770 SCYNEXIS ADPKD
PRESS RELEASE published on 03/31/2026 at 13:07, 7 months 8 days ago Informations privilégiées / Opérations de l'émetteur (acquisitions, cessions...) Poxel annonce la cession du PXL770 à Scynexis pour jusqu'à 196 millions de dollars, renforçant sa position financière. Étude clinique phase 2 prévue pour ADPKD. Accord financier détaillé Cession Accord Financier Poxel PXL770 SCYNEXIS
Published on 11/06/2026 at 22:15, 2 days 1 hour ago Jaguar Health Reports Approval of All Proposals at November 2026 Special Meeting of Stockholders
Published on 11/06/2026 at 13:00, 2 days 11 hours ago Alaska Energy Metals Achieves High Extraction Rates of Metals from Hydromet Testing, Nikolai Nickel Project, Alaska
Published on 11/06/2026 at 12:30, 2 days 11 hours ago Relevant Gold Receives Expanded Drilling Approvals for the Lewiston Project in Wyoming
Published on 11/06/2026 at 12:30, 2 days 11 hours ago Vogenx Reports Third Quarter 2026 Financial Results and Business Highlights
Published on 11/08/2026 at 12:10, 11 hours 51 minutes ago GSMA MWC26 Doha opens with call to align on global industry standards and close MENA's connectivity gap
Published on 11/08/2026 at 10:15, 13 hours 46 minutes ago 2026 China International Intelligent Communication Forum Held in Wuxi
Published on 11/07/2026 at 13:35, 1 day 10 hours ago Eurobattery Minerals board member and CEO remanded in custody in Sweden
Published on 11/06/2026 at 20:15, 2 days 3 hours ago African Medicines Agency Marks First Year of Operations with New Platforms to Strengthen Regulation and Support Manufacturing
Published on 11/06/2026 at 20:15, 2 days 3 hours ago L’Agence africaine des médicaments marque sa première année d’activité avec le lancement de nouvelles plateformes pour renforcer la réglementation et soutenir la fabrication
Published on 11/06/2026 at 19:06, 2 days 4 hours ago ALTAREIT : DÉCLARATION MENSUELLE DES OPÉRATIONS RÉALISÉES PAR LA SOCIÉTÉ SUR SES PROPRES TITRES OCTOBRE 2026
Published on 11/06/2026 at 19:04, 2 days 4 hours ago ALTAREIT : INFORMATION RELATIVE AU NOMBRE TOTAL DE DROITS DE VOTE ET D’ACTIONS COMPOSANT LE CAPITAL SOCIAL
Published on 11/06/2026 at 19:01, 2 days 4 hours ago ALTAREA : DÉCLARATION MENSUELLE DES OPÉRATIONS RÉALISÉES PAR LA SOCIÉTÉ SUR SES PROPRES TITRES OCTOBRE 2026
Published on 11/06/2026 at 19:00, 2 days 5 hours ago ALTAREA : INFORMATION RELATIVE AU NOMBRE TOTAL DE DROITS DE VOTE ET D’ACTIONS COMPOSANT LE CAPITAL SOCIAL
